血清大分子碱性磷酸酶测定对肿瘤的诊断价值

THE VALUE OF THE SERUM HMAP ASSAY IN PATIENTS WITH VARIOUS CANCERS

用特异性大分子碱性磷酸酶(HMAP)单克隆抗体免疫催化测定方法检测了胃、肠、胰、乳腺和甲状腺5种癌症病人血清中HMAP含量。发现在这5种癌症患者血清中HMAP出现的机率较高,与健康人的值差异显著,P<0.001,其中胰、肠、胃癌的阳性率高,分别为87.5%,83.3%和59.0%;与癌胚抗原(CEA)测定结果比较,HMAP的敏感性高于CEA。表明HMAP可能是一种癌相关同工酶,测定患者血清中HMAP含量,对这类肿瘤有辅助诊断价值。

A new immunocatalytical method has been developed to detect high molecular weight alkaline phosphatase(HMAP)in the sera of patients with cancer of the stomach(22 cases),intestine(18 cases),pancreas(8 cases),thyroid(22 cases),and breast(21 cases).It was found that the HMAP we detected more frequently in these sera,especially in the patients with cancer of the stomach,intestine,and pancreas.87.5% of those with pancreatic cancer,83.3% of those with intestinal canser and 59% of those with gastric cancer were positive for HMAP.Compared with the detection rate using CEA.we found that measurement of the HMAP was more sensitive than CEA.It appears that HMAP is a cancer-associated isoenzyme and that the determination of HMAP is very helpful to detect these types of cancers.